What is Vistagen Therapeutics 5-Year Yield-on-Cost %?
Vistagen Therapeutics's yield on cost for the quarter that ended in Dec. 2023 was 0.00.
The historical rank and industry rank for Vistagen Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:
VTGN's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.955 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Competitive Comparison of Vistagen Therapeutics's 5-Year Yield-on-Cost %
For the Biotechnology subindustry, Vistagen Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Vistagen Therapeutics 5-Year Yield-on-Cost % Related Terms
Thank you for viewing the detailed overview of Vistagen Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Vistagen Therapeutics (Vistagen Therapeutics) Business Description
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTGN has been successfully added to your